Skip to main content
. Author manuscript; available in PMC: 2012 May 3.
Published in final edited form as: N Engl J Med. 2011 Nov 3;365(18):1663–1672. doi: 10.1056/NEJMoa1105185

Table 2.

Treatment Effect of Ivacaftor with Respect to the Change from Baseline through Week 48 in the Percent of Predicted FEV1, According to Subgroups.*

Subgroup Treatment Effect P Value
Baseline % of predicted FEV1
 <70% 10.6 <0.001
 ≥70% 10.3 <0.001
Geographic region
 North America 9.0 <0.001
 Europe 9.9 <0.001
 Australia 11.9 0.008
Sex
 Male 11.0 <0.001
 Female 11.6 <0.001
Age
 <18 yr 11.4 0.005
 ≥18 yr 9.9 <0.001
*

The treatment effect represents the difference between the ivacaftor group and the placebo group with respect to the absolute change from baseline through week 48 in the percent of predicted FEV1.